SG Americas Securities’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-167,417
| Closed | -$1.88M | – | 3924 |
|
|
2017
Q3 | $1.88M | Buy |
167,417
+133,669
| +396% | +$1.47M | 0.02% | 838 |
|
|
2017
Q2 | $371K | Buy |
33,748
+5,701
| +20% | +$57K | ﹤0.01% | 2040 |
|
|
2017
Q1 | $275K | Buy |
28,047
+10,598
| +61% | +$106K | ﹤0.01% | 2227 |
|
|
2016
Q4 | $188K | Buy |
+17,449
| New | +$174K | ﹤0.01% | 2410 |
|
|
2016
Q2 | – | Sell |
-12,437
| Closed | -$137K | – | 3221 |
|
|
2016
Q1 | $137K | Buy |
+12,437
| New | +$111K | ﹤0.01% | 2435 |
|
|
2015
Q4 | – | Sell |
-128,589
| Closed | -$892K | – | 3156 |
|
|
2015
Q3 | $892K | Buy |
+128,589
| New | +$1.1M | 0.01% | 881 |
|
|
2015
Q1 | – | Sell |
-10,008
| Closed | -$88K | – | 3308 |
|
|
2014
Q4 | $88K | Buy |
+10,008
| New | +$81K | ﹤0.01% | 2947 |
|
|
2014
Q2 | – | Sell |
-12,494
| Closed | -$57K | – | 2825 |
|
|
2014
Q1 | $57K | Buy |
+12,494
| New | +$60.3K | ﹤0.01% | 2300 |
|
SG Americas Securities's SCLN Position: Q4 2017 in Review
SG Americas Securities sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 167,417 shares — an estimated $1.88M sold.
SG Americas Securities first reported a position in SCLN in Q1 2014 and held it in 8 quarters. The position peaked at $1.88M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- SG Americas Securities reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- SG Americas Securities sold 167,417 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.88M.
- SG Americas Securities first reported a position in Sciclone Pharmaceuticals Inc in Q1 2014 and held it in 8 quarters.
- SG Americas Securities's Sciclone Pharmaceuticals Inc position peaked at $1.88M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on SG Americas Securities's 13F filing for Q4 2017, filed 24 Jan 2018.